Torrent Pharmaceuticals Résultats passés
Passé contrôle des critères 6/6
Torrent Pharmaceuticals a connu une croissance annuelle moyenne de ses bénéfices de 13%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en hausse à 13.4% par an. Les revenus ont augmenté de en hausse à un taux moyen de 7.8% par an. Le rendement des capitaux propres de Torrent Pharmaceuticals est 24% et ses marges nettes sont de 16.1%.
Informations clés
13.0%
Taux de croissance des bénéfices
12.9%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 17.5% |
| Taux de croissance des recettes | 7.8% |
| Rendement des fonds propres | 24.0% |
| Marge nette | 16.1% |
| Dernière mise à jour des bénéfices | 30 Sep 2024 |
Mises à jour récentes des performances passées
Recent updates
Earnings Miss: Torrent Pharmaceuticals Limited Missed EPS By 7.7% And Analysts Are Revising Their Forecasts
Oct 29
Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Popularity With Investors Is Under Threat From Overpricing
Oct 24Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Just Reported And Analysts Have Been Lifting Their Price Targets
Jul 26Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark
Apr 16Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 03Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹22.00
Feb 05Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings
Jan 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly
Nov 14Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jun 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Mar 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 25Torrent Pharmaceuticals' (NSE:TORNTPHARM) Soft Earnings Don't Show The Whole Picture
Jun 02Estimating The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
May 25A Look At The Intrinsic Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Feb 18Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹25.00
Jan 27Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly
Jan 04Here's Why I Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is An Interesting Stock
Dec 14A Look At The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Nov 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Sep 30Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Deserve A Spot On Your Watchlist?
Sep 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 02I Ran A Stock Scan For Earnings Growth And Torrent Pharmaceuticals (NSE:TORNTPHARM) Passed With Ease
Jun 01Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Shares Could Be 30% Above Their Intrinsic Value Estimate
May 14Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 23Ventilation des recettes et des dépenses
Comment Torrent Pharmaceuticals gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Sep 24 | 112,238 | 18,024 | 21,076 | 0 |
| 30 Jun 24 | 109,958 | 17,354 | 20,676 | 0 |
| 31 Mar 24 | 107,278 | 16,564 | 20,166 | 0 |
| 31 Dec 23 | 104,742 | 14,942 | 19,662 | 0 |
| 30 Sep 23 | 102,332 | 13,432 | 18,932 | 0 |
| 30 Jun 23 | 98,642 | 12,692 | 17,842 | 0 |
| 31 Mar 23 | 96,202 | 12,452 | 17,052 | 0 |
| 31 Dec 22 | 92,580 | 8,312 | 16,233 | 0 |
| 30 Sep 22 | 88,750 | 7,972 | 15,883 | 0 |
| 30 Jun 22 | 87,210 | 8,012 | 15,833 | 0 |
| 31 Mar 22 | 85,080 | 7,772 | 15,483 | 0 |
| 31 Dec 21 | 83,158 | 12,189 | 15,227 | 0 |
| 30 Sep 21 | 82,028 | 12,669 | 14,977 | 0 |
| 30 Jun 21 | 80,828 | 12,609 | 14,717 | 0 |
| 31 Mar 21 | 80,046 | 12,519 | 14,597 | 0 |
| 31 Dec 20 | 80,143 | 12,417 | 14,350 | 0 |
| 30 Sep 20 | 79,853 | 11,957 | 14,260 | 0 |
| 30 Jun 20 | 79,733 | 11,297 | 14,210 | 0 |
| 31 Mar 20 | 79,393 | 10,247 | 14,421 | 0 |
| 31 Dec 19 | 78,488 | 5,593 | 14,398 | 0 |
| 30 Sep 19 | 79,338 | 5,543 | 14,538 | 0 |
| 30 Jun 19 | 78,228 | 4,893 | 14,388 | 0 |
| 31 Mar 19 | 76,728 | 4,363 | 14,038 | 0 |
| 31 Dec 18 | 75,141 | 8,161 | 13,743 | 0 |
| 30 Sep 18 | 69,891 | 6,281 | 12,783 | 0 |
| 30 Jun 18 | 65,121 | 6,531 | 12,183 | 0 |
| 31 Mar 18 | 59,498 | 6,781 | 11,353 | 0 |
| 31 Dec 17 | 56,727 | 6,556 | 10,674 | 0 |
| 30 Sep 17 | 56,387 | 8,266 | 10,284 | 0 |
| 30 Jun 17 | 56,387 | 8,296 | 10,044 | 0 |
| 31 Mar 17 | 58,157 | 9,336 | 9,934 | 0 |
| 31 Dec 16 | 59,154 | 10,014 | 10,233 | 0 |
| 30 Sep 16 | 60,144 | 10,624 | 9,913 | 0 |
| 30 Jun 16 | 62,744 | 13,644 | 9,393 | 0 |
| 31 Mar 16 | 66,669 | 17,332 | 8,424 | 0 |
| 31 Dec 15 | 63,315 | 16,299 | 18,653 | 0 |
| 30 Sep 15 | 59,605 | 13,139 | 18,583 | 0 |
| 30 Jun 15 | 54,865 | 9,439 | 18,723 | 0 |
| 31 Mar 15 | 46,535 | 7,509 | 8,772 | 0 |
| 31 Dec 14 | 47,247 | 8,649 | 16,510 | 0 |
| 30 Sep 14 | 45,717 | 8,559 | 16,310 | 0 |
| 30 Jun 14 | 43,267 | 7,709 | 15,890 | 0 |
| 31 Mar 14 | 41,847 | 6,639 | 15,770 | 0 |
| 31 Dec 13 | 38,291 | 5,308 | 13,901 | 0 |
Des revenus de qualité: TORNTPHARM a des bénéfices de haute qualité.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de TORNTPHARM sont plus élevées que l'année dernière TORNTPHARM. (16.1%) sont plus élevées que l'année dernière (13.1%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de TORNTPHARM ont augmenté de 13% par an au cours des 5 dernières années.
Accélération de la croissance: La croissance des bénéfices de TORNTPHARM au cours de l'année écoulée ( 34.2% ) dépasse sa moyenne sur 5 ans ( 13% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices TORNTPHARM au cours de l'année écoulée ( 34.2% ) a dépassé celle du secteur Pharmaceuticals 20%.
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de TORNTPHARM ( 24% ) est considéré comme élevé.